Personalis Further Expands Leadership Team With Appointment of Leslie Grab, VP of Intellectual Property & John Lyle, VP of As...
16 7월 2020 - 9:32PM
Business Wire
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics
for cancer, today announced the appointment of Leslie Grab as VP of
Intellectual Property and John Lyle as VP of Assay Research and
Development.
Dr. Grab joins Personalis from Verily Life Sciences (a Google
spin-out), where she was responsible for worldwide patent &
trademark strategy and portfolio development across multiple
product areas. Prior to that, Dr. Grab worked at the law firm of
Kilpatrick Townsend & Stockton, where she focused on patent
prosecution, technology transactions, and patent litigation in the
fields of chemistry, biochemistry, molecular biology, and medical
diagnostics. Dr. Grab holds a PhD in Biochemistry and Molecular
Biology from Wake Forest University and a BA in Chemistry from
Catawba College, North Carolina. She earned her law degree from the
University of North Carolina, Chapel Hill, where she also served as
a Post-Doctoral Associate researching the inter-relationship
between exosomes and ovarian cancer.
Dr. Lyle joins Personalis after 14 years at Pacific Biosciences
(NASDAQ: PACB), where he most recently served as Senior Director of
Single Molecule Sequencing focusing on reagent, system, and
application development of long-read, ultra-high accuracy
sequencing. Dr. Lyle received his PhD from Stanford University in
Microbiology and Immunology and holds a BS from Bates College,
Maine. Dr. Lyle also served as a Post-Doctoral Fellow at the
University of California, San Francisco, studying the structure and
function of the centrosome.
“We’re very pleased to have such experienced professionals join
our management team here at Personalis,” said John West, Personalis
CEO. “The life sciences experience that both Drs. Grab and Lyle
bring to the organization will assist us to continue our history of
developing innovative and proprietary genomics solutions to address
the needs of our pharmaceutical and institutional partners across
the globe.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis® ImmunoID NeXT Platform®
is designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP-aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
This press release contains or may imply "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements include all statements that are not
historical facts, including, for example, statements relating to
the potential advancement of or growth opportunities for
Personalis’ business, expansion of Personalis’ market presence in
immuno-oncology, the company’s services for the VA Million Veterans
Program, and other future events. These forward-looking statements
are subject to risks and uncertainties, including those related to
the evolution of cancer therapies and market adoption of our
services, our expectations regarding future performance, and the
COVID-19 pandemic, as well as other risks and uncertainties
discussed in Personalis’ filings with the Securities and Exchange
Commission (SEC), including in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic
reports on Forms 10-K and 10-Q and subsequent filings and in the
documents incorporated by reference therein, all of which may
significantly impact our business and operations, the business and
operations of our customers, our ability to access capital and the
value of our common stock. Except as otherwise required by law,
Personalis disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date hereof, whether as a result of new information, future events
or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200716005436/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com 415-202-5678 Media
Contact for Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
